CXCL12/CXCR4 signaling

Patients with glioblastoma multiform (GBM) have an overall median survival of 15 months. This catastrophic survival rate is the consequence of systematic relapses that could arise from remaining glioblastoma stem cells (GSCs) left behind after surgery.

Researchers at GIGA demonstrated that GSCs are able to escape the tumor mass and specifically colonize the adult subventricular zones (SVZs) after transplantation. This specific localization, away from the initial injection site, therefore represents a high-quality model of a clinical obstacle to therapy and relapses because GSCs notably retain the ability to form secondary tumors.

They questioned the role of the CXCL12/CXCR4 signaling in the GSC-specific invasion of the SVZs and demonstrated that both receptor and ligand are respectively expressed by different GBM cell populations and by the SVZ itself.

Using in vitro and in vivo models they revealed the significant role of the CXCL12/CXCR4 signaling in this original model of brain cancer invasion.

Interested in these projects? Drop us an email [info@b2h.be]. We are looking forward collaborating with you!

Related articles

PDC*line Pharma is GMP accredited by the Belgian Federal Agency for Medicines and Health Products (FAMHP) for its Quality Control and Release Activities for PDC*lung, a drug for lung cancer immunotherapy

Liège (Belgium), 21st January 2019. PDC*line Pharma is delighted to announce, that the company is now accredited by the Belgian Federal Agency for Medicines and Health Products (FAMHP) for the Quality Control and Release activities of its anticancer agent PDC*lung, intended for the treatment of patients with lung cancer.  PDC*line Pharma is developing a new

Read more
PDC*line Pharma is GMP accredited by the Belgian Federal Agency for Medicines and Health Products (FAMHP) for its Quality Control and Release Activities for PDC*lung, a drug for lung cancer immunotherapy

First Congress in Health Simulation

The Medical Simulation Center of the University of Liège organizes its first congress in Health Simulation: “Towards evidence-based simulation”. Event will be held on Thursday, March 28th, 2019 in the faculty of medicine amphitheatres of Liège University, located on Sart-Tilman campus. Several themes will be discussed: Evidence-based Innovations and advances in simulation Medical education –

Read more
First Congress in Health Simulation

New University Certificate for clinical trials

The Clinical Sciences Department of the Medicine Faculty of the University of Liège organizes from the academic year 2018-2019 a University Certificate in clinical trials. More information is available in this folder

Read more
New University Certificate for clinical trials